An 11-member advisory panel to the US Food and Drug Administration (FDA) has unanimously concluded that the investigational anti-amyloid donanemab is effective for the treatment of patients with early symptomatic Alzheimer’s disease (AD) and that the potential benefits outweigh the risks in this patient population. The June 10 meeting of the Peripheral and Central Nervous …
